Christoph Rentsch
Director/Board Member chez Targimmune Therapeutics AG
Profil
Christoph Rentsch is currently a Director at Targimmune Therapeutics AG.
He previously worked as a Finance Director at Alusuisse-Lonza America, Inc., an Associate at Credit Suisse AG, and as the Head-Group Funding & Capital Markets at Roche Group.
From 2015 to 2019, he served as the Chief Financial Officer at Santhera Pharmaceuticals Holding AG.
He also worked as the Chief Financial Officer at Spexis Ltd., Treasurer at Alusuisse Group Ltd., and Partner at Caperis Partners AG.
Additionally, he served as a Member-Supervisory Board at Cellestia Biotech AG.
Mr. Rentsch obtained an undergraduate degree from the University of Applied Sciences Basel.
Postes actifs de Christoph Rentsch
| Sociétés | Poste | Début |
|---|---|---|
Targimmune Therapeutics AG
 Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Anciens postes connus de Christoph Rentsch
| Sociétés | Poste | Fin |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Director of Finance/CFO | 31/12/2019 |
Cellestia Biotech AG
 Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Credit Suisse AG
 Credit Suisse AG Investment ManagersFinance Credit Suisse AG is an investment management firm headquartered in Zurich, Switzerland. The firm was founded in 1856 and was acquired by UBS Group AG (SWX: UBSG) from Credit Suisse Group AG in 2023. Credit Suisse manages global and regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals worldwide. They also offer private banking and wealth management, investment banking, and corporate and business support services. | Corporate Officer/Principal | - |
| Alusuisse-Lonza America, Inc. | Director of Finance/CFO | - |
| Alusuisse Group Ltd. | Treasurer | - |
Formation de Christoph Rentsch
| University of Applied Sciences Basel | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| SPEXIS AG | Health Technology |
| Entreprise privées | 7 |
|---|---|
Credit Suisse AG
Credit Suisse AG Investment ManagersFinance Credit Suisse AG is an investment management firm headquartered in Zurich, Switzerland. The firm was founded in 1856 and was acquired by UBS Group AG (SWX: UBSG) from Credit Suisse Group AG in 2023. Credit Suisse manages global and regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals worldwide. They also offer private banking and wealth management, investment banking, and corporate and business support services. | Finance |
Roche Group
 Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
| Alusuisse Group Ltd. | Distribution Services |
| Alusuisse-Lonza America, Inc. | |
| Caperis Partners AG | |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Health Technology |
